Proposing A Novel Glutamatergic Regimen as a Missing Link in ADHD Treatment

Attention-deficit/hyperactivity disorder (ADHD) is now viewed less as a single catecholamine deficit and more as a timing error in the dialogue between dopamine (DA) and glutamate. Although psychostimulants offer robust symptom relief, many adults continue to report executive dysfunction and "brain fog." This article explores whether the oral "Cheung Glutamatergic Regimen"—originally designed to replicate ketamine-like neuroplasticity—could close that therapeutic gap. After summarising evidence on disrupted DA–glutamate coupling in ADHD, the paper outlines two stimulant-specific adaptations of the Cheung protocol: (a) methylphenidate paired with piracetam, and (b) amphetamine combined with dextromethorphan and piracetam. The discussion concludes with pharmacokinetic cautions surrounding CYP2D6 inhibition and suggestions for future research.